Palbociclib shows promise in patients with hormone-resistant breast cancer

20 febrero 2015

Palbociclib, an investigational oral medication that works by blocking molecules responsible for cancer cell growth, is well tolerated and extends progression-free survival in newly diagnosed, advanced breast cancer patients, including those whose disease has stopped responding to traditional endocrine treatments.